Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912774 | 1.00 | RIPK1 (0.67) | RIPK1KDM4EALDH1A1PTGDR2RAB9A | |
| SCHEMBL22447818 | 0.81 | KDM4E (0.48) | RIPK1KDM4EALDH1A1PTGDR2RAB9A | |
| SCHEMBL17882287 | 0.80 | RIPK1 (1.00) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL22447788 | 0.76 | CNR2 (0.56) | KDM4EALDH1A1RAB9A | |
| SCHEMBL14630008 | 0.74 | PTGDR2 (0.54) | RIPK1KDM4EALDH1A1PTGDR2 | |
| SCHEMBL21362892 | 0.72 | BCHE (0.49) | KDM4EALDH1A1 | |
| SCHEMBL3628742 | 0.72 | BCHE (0.49) | KDM4EALDH1A1 | |
| SCHEMBL29912752 | 0.71 | RIPK1 (0.50) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL17882280 | 0.71 | RIPK1 (0.50) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL13058298 | 0.70 | BCHE (0.50) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224237-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| US-20180263934-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-20 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| WO-2016101885-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682319-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885KDM4E 3910/4885ALDH1A1 4104/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885KDM4E 1232/4885ALDH1A1 2786/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885KDM4E 1232/4885ALDH1A1 2786/4885 |
| US-20170290790-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885KDM4E 3458/4885ALDH1A1 3900/4885 |
| US-20180263934-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885KDM4E 3910/4885ALDH1A1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.